Gilead Sciences Stock Drops as Latest Data on Coronavirus Drug Not Good Enough

Gilead Sciences
stock is falling following the latest data from its trials of remdesivir in patients with Covid-19. Gilead said that in its late-stage clinical trials of remdesivir in patients who … [+2919 chars]Source